MedTrace Logo

Vitamin D and Calcium Supplementation in Breast Cancer

NCT05523609 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-12-01

No results posted yet for this study

Summary

This study aims at assessing the vitamin Dstatus in breast cancer patients who receive letrozole for more than two months and to evaluate effects of vitamin D3 and calcium supplementation on arthalgia caused by letrozole on these patients.

Conditions

Interventions

DRUG

Letrozole 2.5mg

20 patients will receive Letrozole only for 12 weeks

DRUG

Letrozole + vitamin D3 and calcium

20 patients will receive Letrozole in addition to 2000 IU vitamin D3 per day for 12 weeks.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Sahar K Hegazy, Professor · Head of clinical Pharmacy Department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2024-09-30
Completion
2024-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05523609 on ClinicalTrials.gov